Agilent Technologies's biggest risks in the FY2024 10-K
- Agilent relies heavily on global life sciences and pharmaceutical markets, international operations, and continuous new product introductions to drive growth.
The risks most specific to Agilent Technologies
- Business and Strategic Risks
Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated
Our quarterly sales and operating results depend heavily on order volume and timing from customers in cyclical markets with limited visibility.
- Business and Strategic Risks
Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies
Demand for our products relies on customer capital spending and research budgets, including pharmaceutical companies, laboratories, universities, and government agencies.
- Regulatory, Legal and Compliance Risks
We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations
We are subject to extensive regulation by the FDA and similar foreign agencies for many of our products and services.
- Regulatory, Legal and Compliance Risks
Some of our products are subject to particularly complex regulations such as regulations of toxic substances, and failure to comply with such regulations could harm our business
Some of our products and consumables are regulated by the EPA under the Toxic Substances Control Act and similar foreign laws.
- Financial and Tax Risks
If tax incentives change or cease to be in effect, our income taxes could increase significantly
Our taxes could increase significantly if tax incentives granted by Singapore to our foreign subsidiaries are not renewed upon expiration.
- Financial and Tax Risks
We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations
We are party to a $1.5 billion unsecured credit facility expiring June 7, 2028, and a $300 million uncommitted credit line.
- Financial and Tax Risks
Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity
As of October 31, 2024, we held $1,329 million in cash and cash equivalents exposed to financial market disruptions.
All 32 risk factors
Headings as the filing states them, in filing order.
Business and Strategic Risks
- 01General economic conditions may adversely affect our operating results and financial condition
- 02Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated
- 03If we do not introduce successful new products and services in a timely manner to address increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards, our products and services may become obsolete, and our operating results may suffer
- 04Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations
- 05Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies
- 06Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income
- 07Our business will suffer if we are not able to retain and hire key personnel
- 08Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business, and we may not realize the operational or financial benefits from such actions
- 09Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected
- 10The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business
- 11Public health crises such as the COVID-19 pandemic may adversely impact, and pose risks to, certain elements of our business, results of operations and financial condition, the nature and extent of which are highly uncertain and unpredictable
Regulatory, Legal and Compliance Risks
- 12If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price
- 13We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations
- 14Some of our products are subject to particularly complex regulations such as regulations of toxic substances, and failure to comply with such regulations could harm our business
- 15Our business may suffer if we fail to comply with government contracting laws and regulations
- 16Our reputation, ability to do business and financial statements may be harmed by improper conduct by any of our employees, agents or business partners
- 17We are subject to evolving corporate governance and public disclosure expectations and regulations that impact compliance costs and risks of noncompliance
- 18Environmental contamination from past and ongoing operations could subject us to substantial liabilities
- 19We are subject to environmental laws and regulations that expose us to a number of risks and could result in significant liabilities and costs
- 20Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services
- 21Third parties may infringe our intellectual property, and we may suffer competitive injury or expend significant resources enforcing our rights
Operational Risks
- 22Our operating results may suffer if our manufacturing capacity does not match the demand for our products
- 23If we are unable to successfully manage the consolidation and streamlining of our manufacturing operations, we may not achieve desired efficiencies, and our ability to deliver products to our customers could be disrupted
- 24If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations could be seriously harmed
- 25If we experience a significant disruption in, or breach in security of, our information technology systems, or if we fail to implement new systems and software successfully, our business could be adversely affected
Financial and Tax Risks
- 26Our retirement and post retirement pension plans are subject to financial market risks that could adversely affect our future results of operations and cash flows
- 27Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on our results of operations, financial condition and liquidity
- 28If tax incentives change or cease to be in effect, our income taxes could increase significantly
- 29We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations
- 30borrowing for general corporate purposes, future acquisitions, expansion of our business or repurchases of our outstanding shares of common stock
- 31We cannot assure that we will continue to pay dividends on our common stock
- 32Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity
Other Agilent Technologies 10-Ks
- FY2025 10-K risk factors33 risks3 new2 dropped7 reworded
Foreign currency and hedging exposures expanded with new bank counterparty risks.
Filed Dec 22, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.